What does this research mean for the field?

A prolonged-release combined oral contraceptive containing 2-mg dienogest and 0.02-mg ethinylestradiol in an extended 181-day regimen provides a high rate of no bleeding days and high user satisfaction, offering a solid alternative to immediate-release formulations. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This trial aims to evaluate the safety, tolerability, and bleeding pattern of prolonged-release contraceptive formulations containing dienogest and ethinylestradiol.

June 10, 2026International Journal of Clinical PracticeOpen Access

Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol

View Full Paper

Ask AI

Bookmark

Authors

PRPedro-Antonio Regidor AAAlicyoy AnguloMadrid Health Service AMAlejandro Munoz

Discussion

Member takes

Implication

Randomized trial investigates bleeding patterns and safety of prolonged-release contraceptives in women, suggesting effective long-term use options.

Key Points

This trial aims to evaluate the safety, tolerability, and bleeding pattern of prolonged-release contraceptive formulations containing dienogest and ethinylestradiol.
Multicenter, open-label, active-controlled trial with four parallel groups.
Participants included females aged 18–35 receiving different doses of extended-release and comparator formulations.
Each treatment period consisted of 87 days of active treatment followed by a 4-day tablet-free interval.
In the 2-mg DNG/0.02-mg EE group, scheduled bleeding days reduced significantly from 7.4 to 2.4 during the treatment periods.
Unscheduled bleeding days decreased from 18.3 to 9.7 for the 2-mg DNG/0.02-mg EE group, contrasting with increased rates for the comparator.
Satisfaction rates were high, with 87.5% for the 2-mg DNG/0.02-mg EE group.

Cite This Study

Regidor et al. (2026) studied this question.

synapsesocial.com/papers/6a2900886f82f25be989d13d https://doi.org/10.1155/ijcp/7744486

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial investigates bleeding patterns and safety of prolonged-release contraceptives in women, suggesting effective long-term use options.

Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider